KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) EBT: 2009-2024

Historic EBT for Emergent BioSolutions (EBS) over the last 16 years, with Dec 2024 value amounting to -$142.9 million.

  • Emergent BioSolutions' EBT fell 59.55% to $57.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $105.9 million, marking a year-over-year increase of 162.37%. This contributed to the annual value of -$142.9 million for FY2024, which is 80.46% up from last year.
  • Emergent BioSolutions' EBT amounted to -$142.9 million in FY2024, which was up 80.46% from -$731.2 million recorded in FY2023.
  • In the past 5 years, Emergent BioSolutions' EBT ranged from a high of $411.9 million in FY2020 and a low of -$731.2 million during FY2023.
  • In the last 3 years, Emergent BioSolutions' EBT had a median value of -$219.0 million in 2022 and averaged -$364.4 million.
  • In the last 5 years, Emergent BioSolutions' EBT surged by 432.17% in 2020 and then plummeted by 233.88% in 2023.
  • Yearly analysis of 5 years shows Emergent BioSolutions' EBT stood at $411.9 million in 2020, then dropped by 26.39% to $303.2 million in 2021, then slumped by 172.23% to -$219.0 million in 2022, then plummeted by 233.88% to -$731.2 million in 2023, then spiked by 80.46% to -$142.9 million in 2024.